Rubius therapeutics, inc. (RUBY)
Balance Sheet / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Dec'17
Assets
Current assets:
Cash and cash equivalents

144,517

91,898

109,611

141,084

192,499

307,064

354,786

116,922

104,288

Investments

96,874

191,389

215,078

221,246

186,414

96,987

54,088

-

-

Marketable securities

-

-

-

-

-

-

-

64,808

-

Prepaid expenses and other current assets

4,491

5,979

5,073

4,196

6,799

9,737

3,492

965

700

Restricted cash

-

-

-

122

122

600

122

122

-

Total current assets

245,882

289,266

329,762

366,648

385,834

414,410

412,488

182,817

104,988

Operating lease, right-of-use-asset

43,998

46,559

47,900

27,600

29,200

-

-

-

-

Property, plant and equipment, net

56,383

56,924

52,478

41,898

24,577

62,796

39,208

21,130

2,415

Restricted cash

1,735

1,735

1,735

1,735

1,735

1,735

1,102

1,102

284

Other assets

329

357

386

108

138

168

-

-

-

Deferred offering costs

-

-

-

-

-

-

-

2,484

-

Total assets

348,327

394,841

432,272

438,032

441,470

479,109

452,798

207,533

107,687

Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable

7,626

7,178

11,679

2,344

10,200

7,886

4,542

6,967

2,033

Accrued expenses and other current liabilities

10,291

16,042

14,866

13,805

5,975

12,118

10,245

7,635

2,986

Operating lease liabilities

9,433

10,540

6,998

5,076

4,525

-

-

-

-

Current portion of long-term debt

-

-

-

-

-

-

1,222

306

2,139

Total current liabilities

27,350

33,760

33,543

21,225

20,700

20,004

16,009

14,908

7,158

Long-term debt, net of discount

49,683

49,596

49,509

49,422

24,431

24,347

4,245

5,156

3,302

Deferred rent

-

-

-

-

-

-

144

140

158

Preferred stock warrant liability

-

-

-

-

-

-

-

2,627

866

Liability for early exercise of stock options and restricted stock

-

-

-

-

144

-

187

223

100

Other long-term liabilities

371

405

438

604

506

309

-

-

-

Operating lease liabilities, net of current portion

35,766

36,867

41,439

23,137

24,053

-

-

-

-

Lease financing obligation

-

-

-

-

-

41,441

21,206

14,412

-

Total liabilities

113,170

120,628

124,929

94,388

69,834

86,101

41,791

37,466

11,584

Commitments and contingencies (see Note 9)

-

-

-

-

-

-

0

0

-

Convertible preferred stock (Series A, B and C), $0.001 par value; no shares and 44,070,808 shares authorized at December 31, 2018 and 2017, respectively; no shares and 43,933,006 shares issued and outstanding at December 31, 2018 and 2017, respectively

-

-

-

-

-

-

-

240,776

139,790

Stockholders' equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized at March 31, 2020 and December 31, 2019; no shares issued or outstanding at March 31, 2020 and December 31, 2019

-

-

-

-

-

-

0

-

-

Common stock, $0.001 par value; 150,000,000 shares authorized at March 31, 2020 and December 31, 2019; 80,429,966 and 80,016,245 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively

80

80

80

80

80

79

79

15

15

Additional paid-in capital

595,772

586,798

575,365

564,527

553,338

543,040

533,846

34,636

17,277

Accumulated other comprehensive income

531

75

166

290

81

-29

-19

-27

-

Accumulated deficit

-361,200

-312,740

-268,268

-221,253

-181,863

-150,082

-122,899

-105,333

-60,979

Total stockholders' equity

235,157

274,213

307,343

343,644

371,636

393,008

411,007

-70,709

-43,687

Total liabilities and stockholders' equity

348,327

394,841

432,272

438,032

441,470

479,109

452,798

207,533

107,687